(5S,6R)-METHYL 5,6,7-TRIHYDROXYHEPTANOATE
(5S,6R)-METHYL 5,6,7-TRIHYDROXYHEPTANOATE
(5S,6R)-METHYL 5,6,7-TRIHYDROXYHEPTANOATE 性质
| 沸点 | 360.8±42.0 °C(Predicted) |
|---|---|
| 密度 | 1?+-.0.06 g/cm3(Predicted) |
| 储存条件 | -20°C |
| 溶解度 | H2O：≥20mg/mL |
| 酸度系数(pKa) | 13.74±0.20(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
| 稳定性 | 自购买之日起，稳定期为 1 年。 其DMSO 或乙醇溶液可在 -20°C 下保存长达 3 个月。 |
(5S,6R)-METHYL 5,6,7-TRIHYDROXYHEPTANOATE 用途与合成方法
Lipoxin A4 receptor
Angiotensin converting enzyme (ACE)
In H22 cells, BML-111 inhibits the production of vascular endothelial growth factor and reduces hypoxia-inducible factor-1α level.
BML-111 inhibits leukotriene B4-induced cellular migration with an IC
50
of 5 nM.
BML-111 (1 mg/kg; intraperitoneal injection; for 15 days; male Imprinting Control Region mice) treatment suppresses tumor-related angiogenesis and tumor growth in vivo. BML-111 also enhances the in situ apoptosis while inhibiting macrophage infiltration in tumor tissue.
BML-111 protects LPS-induced acute lung injury and LPS/D-GalN-induced acute liver injury. BML-111 represses the activity of ACE, but increases the activity of ACE2. BML-111 decreases the expression levels of ACE, AngII, and AngII type 1 receptor (AT1R), meanwhile increases the levels of ACE2, angiotensin-(1-7) (Ang-1-7), and Mas.
| Animal Model: | Male Imprinting Control Region mice (5-6-week-old,18-22 g) injected with H22 cells |
| Dosage: | 1 mg/kg |
| Administration: | Intraperitoneal injection; injected 5 minutes before and 4 hours after H22 cell inoculation, then every 12 hours for 2 consecutive days, then daily in an additional 3 days and every other day for the last 10 days |
| Result: | Suppressed tumor-related angiogenesis and tumor growth in vivo. |
(5S,6R)-METHYL 5,6,7-TRIHYDROXYHEPTANOATE 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-100450 | 1 mg | 2020 | ||
| 2024-04-30 | HY-100450 | (5S,6R)-METHYL 5,6,7-TRIHYDROXYHEPTANOATE | 78606-80-1 | 5mg | 5050 |
